相关实验视频

Updated: May 13, 2026

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

在先进的固体瘤患者中,首次对口服生物可用血管破坏剂DX1002进行人体第一阶段研究

Xiao-Li Wei¹, Hao-Xiang Wu², Dan-Yun Ruan²

¹Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou 510060, P.R. China.

Cell reports. Medicine

|February 19, 2025

概括

DX1002是一种口服血管破坏剂,在固体瘤中显示了初步的抗瘤疗效. 第一阶段试验确定了安全剂量,并观察到大多数患者的疾病稳定,这表明癌症治疗的潜力.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

DX1002是一种口服血管破坏剂,在破坏瘤血管和引起亡方面具有临床前的有效性.
临床前研究表明,在各种动物模型中显著的瘤破坏和亡.

研究的目的:

评估DX1002在患有固体瘤的患者的安全性,耐受性和初步疗效.
为了确定DX1002.2.的最大耐受剂量 (MTD) 和推的第二阶段剂量 (RP2D).

主要方法:

一项1期临床试验,涉及17名患有固体瘤的患者,接受DX1002 (50-1,100毫克) 的升级剂量.
评估与治疗相关的不良事件,最大耐受剂量,推的第二阶段剂量和抗瘤反应.
利用对比增强超声波观察瘤血液输液的变化.

主要成果:

最大耐受剂量和推的第二阶段剂量为每天一次600毫克.
常见的不良事件包括恶心 (23.5%),吐 (17.6%) 和疲劳 (11.8%).
17名患者中有12名患者实现了稳定疾病,其中一名非小细胞肺癌患者维持了6.5个月. 病情进展的中位时间为2.70个月.

结论:

在实体瘤患者中,DX1002在推的第二阶段剂量下耐受良好.
观察到初步的抗瘤疗效,包括大多数患者的稳定疾病.
需要在第二阶段试验中进行进一步的研究,以确认DX1002.2.的疗效.

关键词:

在 DX10022 中使用.第一个阶段的试验.临床前研究的临床前研究.固体瘤是一种固体瘤.血管破坏性剂血管破坏性剂

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research

Published on: May 5, 2021

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...